Wednesday 6th October 2004

08.00 am onwards
Registration

08.55-09.00
Welcome to Dublin and Opening Remarks
HAH 2004 Conference Chairman:
Professor Mark C. Glassy (Rajko Medinica Research Foundation, Shantha West, UCSD, USA)

SESSION 1:
OPENING PLENARY SESSION

Moderator:
Professor Mark C. Glassy (Rajko Medinica Research Foundation, Shantha West, UCSD, USA)

09.00-09.45
Plenary Lecture:
‘Update on chimeric and humanized monoclonal antibodies in cancer therapy’
Robert O. Dillman (Hoag Cancer Center, Newport Beach, California, USA)

SESSION 2:
CANCER I

Moderators:
H. Peter Vollmers (University of Wurzburg, Germany)
Mark C. Glassy (Rajko Medinica Research Foundation, Shantha West, UCSD, USA)

09.45-10.05
‘Lipoptosis, tumor-specific cell death via lipid accumulation induced by human monoclonal IgM antibody SAM-6’
H. Peter Vollmers, T. Pohle, H.K. Muller-Hermelink, S. Brandlein (University of Wurzburg, Germany)

10.05-10.25
‘New mechanistic classes of antibody therapeutic for the potential treatment of tumor progression and angiogenesis’
Clive R. Wood (Dyax Corp, Cambridge, Massachusetts, USA)

10.25-10.45
‘Three ways to kill cancer cells with human antibodies’
Nils Lonberg (Medarex, Milpitas, California, USA)

10.45-11.05
‘Anti-tumor monoclonal antibody effects on human NK cells’
G.J. Weiner, J.A. Bowles, C.M. Taylor, M.E. Shannon, B.K. Link (University of Iwoa, Iwoa City, USA)

11.05-11.30
Coffee Break & Posters

SESSION 3:
CANCER II

Moderators:
H. Peter Vollmers (University of Wurzburg, Germany)
Mark C. Glassy (Rajko Medinica Research Foundation, Shantha West, UCSD, USA)

11.30-12.00
Keynote Lecture:
‘Antibody cocktails for oncology’
Mark C. Glassy (Rajko Medinica Research Foundation, Shantha West, UCSD, USA)

12.00-12.20
‘CFR-1 as a new diagnostic tool for prostate cancer precursors defined by the human monoclonal IgM antibody PAM-1’
Stephanie Brandlein, P. Strobel, E. Wozniak, H.K. Muller-Hermelink, H.P. Vollmers (University of Wurzburg, Germany)

12.20-12.40
‘Expression and production of biologically active anti-tumoral antibodies in transgenic plant systems’
Iann Rance, G. Wallis, V. Jonval, H. Laparra, N. Duchateau, D. Burtin, M. McKnight, M. Glassy (Meristem Therapeutics, Clermont-Ferrand, France)

12.40-13.00
‘Altering distribution and pharmacokinetics of an Fab through association with albumin’
Mark S. Dennis, D.L. Dugger, J. Kowaslki, S. Williams, M. Zhang, P. McDonald, A. Nguyen, A. Reyes, W.L. Wong, L.A. Damico, R.H. Schwall (Genentech Inc, South San Francisco, USA)

13.00-14.00
Lunch Break & Posters

SESSION 4:
CANCER III

Moderator:
H. Peter Vollmers (University of Wurzburg, Germany)

14.00-14.20
‘Phase I Pretarget Radioimmunotherapy (RIT) trial with a novel anti-TAG-72 fusion protein’
Andres Forero-Torres, S. Shen, H. Breitz, R.B. Sims, D.B. Axworthy, K.H. Chen, D.T. Chen, I. Percent, S. Besh, A.F. LoBuglio, R.F. Meredith (University of Alabama at Birmingham, Alabama, USA)

14.20-14.40
‘Generating therapeutic antibodies using phage display technology’
Yan Wu (Genentech Inc, South San Francisco, USA)

14.40-15.00
‘Agensys – Development of a rich antibody product pipeline to novel targets’
Aya Jakobovits (Agensys Inc., Santa Monica, California, USA)

15.00-15.20
‘Promising tumor recognizing capacity of B cells in breast carcinomas. The ‘Proof of Principle’’
Beatrix Kotlan, Jean-Luc Teillaud, Jozsef Toth, Peter Simsa, Wolf-Herman Fridman, Michael McKnight, Mark C. Glassy (National Medical Center, Budapest, Hungary)

15.20-15.40
Comparison of Rituximab-mediated interferon-production and cytotoxicity by human NK cells’
Sebastien Dall’Ozzo, Pierre Bardos, Herve watier, Gilles Thibault (Universite Francois Rabelais de Tours, France)

15.40-16.00
Tea Break & Posters

16.00-16.30
‘Cancer Immunotherapy’
Zdenka K. Jonak (GlaxoSmithKline, USA)

16.30-16.50
‘The rationale and reality of treating cancer with RNA damaging agents’
Nigel S. Courtenay-Luck, Susanna Rybak, Dianne Newton (Antisoma Research Ltd, London, UK)

16.50-17.10
‘Generation and characterisation of a recombinant immunocytokine fusion, which targets a tumour-specific isoform of fibronectin’
Rakesh Verma et al. (Antisoma Research Ltd, London, UK)

SESSION 5:
AUTOIMMUNITY

Moderator:
Yehuda Shoenfeld (Tel-Aviv University, Israel)

17.10-17.55
Keynote Lecture:
‘Autoantibodies – the three Ps: Predicitive, Pathogenic and Protective’
Yehuda Shoenfeld (Tel-Aviv University, Israel)

17.55-18.25
‘Generation of anti-CD44-rheumatoid arthritis-specific monoclonal antibodies’
David Naor and Itshak Golan (The Hebrew University, Jerusalem, Israel)

Evening:
HAH 2004 Conference Dinner